Supernus Pharmaceuticals (SUPN) Enterprise Value (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Enterprise Value data on file, last reported at -$384.2 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 17.12% year-over-year to -$384.2 million in Q1 2026; TTM through Mar 2026 was -$384.2 million, a 17.12% increase from a year earlier, with the FY2025 full-year figure at -$308.7 million, up 31.95% from the prior year.
• Enterprise Value for Q1 2026 stood at -$384.2 million, down from -$308.7 million in the prior quarter.
• Over the last five years, Enterprise Value for SUPN reached as high as -$151.7 million in Q2 2023 and fell as low as -$522.6 million in Q2 2025.
• Historically, Enterprise Value has averaged -$342.6 million across 5 years, with a median of -$347.2 million in 2024.
• Across the five-year window, Enterprise Value surged 57.97% in 2023 and sank 128.93% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$461.3 million in 2022, then jumped by 44.75% to -$254.9 million in 2023, then plunged by 77.97% to -$453.6 million in 2024, then soared by 31.95% to -$308.7 million in 2025, then declined by 24.48% to -$384.2 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$384.2 million in Q1 2026, -$308.7 million in Q4 2025, and -$281.2 million in Q3 2025.